

**2018**

# **Treatment workbook**

*France*

---

## 2018 National report (2017 data) to the EMCDDA by the French Reitox National Focal Point

**Supervision:** Julien Morel d'Arleux

**Coordination and editorial:** Aurélie Lermenier-Jeannet et Anne de l'Eprevier

### Contribution to the workbooks

- 1.1 *Drug Policy:* Cristina Díaz-Gómez, Julie-Émilie Adès
- 1.2 *Legal Framework:* Caroline Protais, Cristina Díaz-Gómez
- 2 *Drugs:* Olivier Le Nézet, Thomas Néfau, Michel Gandilhon, Agnès Cadet-Taïrou, Eric Janssen, Julie-Émilie Adès
- 3.1 *Prevention:* Carine Mutatayi
- 3.2 *Treatment:* Christophe Palle, Anne-Claire Brisacier
- 3.3 *Best Practice:* Carine Mutatayi
- 3.4 *Harms and Harm Reduction:* Anne-Claire Brisacier, Cristina Díaz-Gómez, Thomas Néfau, Agnès Cadet-Taïrou
- 4 *Drug Market and Crime:* Michel Gandilhon, Thomas Néfau, Caroline Protais
- 5.1 *Prison:* Caroline Protais, Anne-Claire Brisacier
- 5.2 *Research:* Isabelle Michot, Maitena Milhet

**Proofreading (French version):** Julie-Émilie Adès, Julien Morel d'Arleux, Ivana Obradovic (OFDT) ; Nicolas Prisse, president of the Interministerial Mission for Combating Drugs and Addictive Behaviours, and the project managers of the MILDECA

**Proofreading (English version):** Anne de l'Eprevier

**Bibliographic references:** Isabelle Michot

**Legal references:** Anne de l'Eprevier

## Table of Contents

<b>T0. Summary</b> .....	3
<b>T1. National profile</b> .....	4
<b>T1.1 Policies and coordination</b> .....	4
<b>T1.2 Organisation and provision of drug treatment</b> .....	5
<b>Outpatient network</b> .....	5
<b>Inpatient network</b> .....	8
<b>T1.3 Key data</b> .....	10
<b>T1.4 Treatment modalities</b> .....	13
<b>Outpatient and Inpatient services</b> .....	13
<b>Opioid substitution treatment (OST)</b> .....	15
<b>T1.5 Quality assurance of drug treatment services</b> .....	19
<b>T2. Trends</b> .....	20
<b>T3. New developments</b> .....	27
<b>T4. Additional information</b> .....	27
<b>T5. Sources and methodology.</b> .....	28

## T0. Summary

Please provide an abstract of this workbook (target: 500 words) under the following headings:

- National profile
- Trends
- New developments

Please include here a brief description of:

- The main treatment-related objectives of the national drug strategy, and the co-ordination bodies responsible for their funding and provision.
- An overview of the main providers of outpatient and inpatient treatment.
- The main treatment modalities available in your country.

Provide a short description of key data on clients profile and patterns of drug use

- National profil

There are two schemes available for dispensing treatments to people using illicit drugs: the specialised addiction treatment system (in socio-medical establishments) and the general healthcare system (hospitals and general practitioners). According to CSAPA activity reports, approximately 138,000 individuals were received in outpatient CSAPA (specialised addiction treatment centres) in 2016 for problems with illegal drugs or diverted psychotropic medications. In 2017, slightly more than 58,000 users starting a course of treatment in a CSAPA were actually included in TDI data. However, these figures account for only a proportion of users corresponding to exhaustive data collection.

OST is mainly prescribed in a primary care setting by general practitioners, and is usually dispensed in community pharmacies. In 2017, 162,300 persons received opioid substitution treatment dispensed in community pharmacies and 23,330 patients received treatment dispensed in a CSAPA in 2016.

In terms of outpatient treatment provision, the public authorities developed specific healthcare for young users by creating youth addiction outpatient clinics (CJC) in 2004. Presently, approximately 540 clinics have opened. Although no national "programmes" intended for other target groups exist, some CSAPA have specialised in healthcare adapted to specific populations (women with children, offenders, etc.).

- Trends

Among those managed for the first time in the specialised addiction treatment structure, the proportion of cannabis users has stabilised after increasing between 2007 and 2014. The proportion of opiate users, which showed a downward trend, has also stabilised in a symmetrical manner. In 2017, this population, with an average age of 27,3 (median age of 24) comprises nearly 74% cannabis users, 14% opioid users and 8% cocaine users.

As regards all treatment entrants, the distribution according to substances seems fairly stable up to 2010, with a slight downward trend in the percentage of cannabis users. However, the share of these users increases then sharply and amounts to 62% in 2016 and decreases for the first time since 2010 in 2017. The evolution of the share of opiate users is roughly symmetrical to that of cannabis users.

Furthermore, since 2013, the number of persons receiving opioid substitution treatment (OST) has remained stable, after increasing constantly since this type of treatment was first introduced. The number of persons treated with buprenorphine decreased slightly over this period, in favour of patients treated with methadone, in keeping with sales data for these opioid substitution medications.

- New developments

The proportion of new patients treated for a cannabis problem is high (59%), but decreased between 2016 and 2017. The proportion of opiate users followed a symmetrical progression to that of cannabis users. The proportion of cocaine users markedly increased between 2016 and 2017. The developments in 2017 contrast with the trends emerging in 2010-2011.

In 2017, 162,300 people received opioid substitution treatment dispensed in community pharmacies: 99,900 were prescribed buprenorphine (Subutex® or generics), 61,700 methadone and 7,600 buprenorphine in combination with naloxone (Suboxone®).

Furthermore, 23,330 patients were dispensed opioid substitution medications in CSAPA (19,800 methadone and 3,530 buprenorphine) in 2016.

## T1. National profile

### T1.1 Policies and coordination

The purpose of this section is to

- describe the main treatment priorities as outlined in your national drug strategy or similar key policy documents
- provide an overview of the co-ordinating/governance structure of drug treatment within your country

Please structure your answers around the following questions.

T1.1.1 What are the main treatment-related objectives of the national drug strategy? (Suggested title: Main treatment priorities in the national drug strategy.)

#### **Main treatment priorities in the national drug strategy**

As regards the management of addiction, the 2018-2022 National Action Plan on Addiction (MILDECA 2018) defines six objectives:

- 1) Allow for the routine and stepped up detection of addictive behaviours
- 2) Increase the role of front-line professionals in supporting patients suffering from addictions
- 3) Develop and promote the adoption of best practice guidelines in addiction medicine
- 4) Reform professional practices
- 5) Structure the addiction medicine healthcare pathway
- 6) Open up healthcare pathways to the disabled

T1.1.2 Who is coordinating drug treatment and implementing these objectives?

(Suggested title: Governance and coordination of drug treatment implementation.)

#### **Governance and coordination of drug treatment implementation**

See T1.1 in the "Drug policy" workbook

T1.1.3 **Optional.** Please provide any additional information you feel is important to understand the governance of treatment within your country.

## T1.2 Organisation and provision of drug treatment

The purpose of this section is to

- describe the organisational structures and bodies that actually provide treatment within your country
- describe the provision of treatment on the basis of Outpatient and Inpatient, using the categories and data listed in the following tables. Drug treatment that does not fit within this structure may be included in the optional section
- provide a commentary on the numerical data submitted through ST24
- provide contextual information on the level of integration between the different treatment providers (e.g. umbrella organizations providing multiple services, for instance both outpatient and low threshold services);

Please structure your answers around the following questions.

### Outpatient network

T.1.2.1 Using the structure and data provided in table I please provide an overview and a commentary of the main bodies/organisations providing Outpatient treatment within your country and on their respective total number of clients receiving drug treatment.

(Suggested title: Outpatient drug treatment system – Main providers and client utilisation.)

#### **Outpatient drug treatment system – Main providers**

There are two schemes available for dispensing treatments to people using illicit drugs (DU): the specialised addiction treatment system (in socio-medical establishments) and the general healthcare system (hospitals and general practitioners). Only those individuals overseen by the professionals mentioned in Table I will be described herein.

##### *The specialised scheme*

Until 2004, illegal drug users were only overseen at specialised care centres for drug users (CSST). Outpatient alcoholism treatment centres (CCAA) only received individuals with alcohol problems. After this date, both categories of centres adopted the same name, national treatment and prevention centres for addiction (CSAPA), and in 2008 were assigned the joint task of treating all individuals with an addiction problem, irrespective of the substance, nonetheless with the possibility of retaining their previous specialisation. Until 2010-2011, the latter maintained a strong presence and the number of illegal drug users admitted in the former CCAA has remained negligible. CSAPA which had previously been outpatient alcoholism treatment centres were not therefore taken into account in TDI data. However, the gradual increase in the number of DU receiving treatment in former CCAA now means that it is no longer appropriate to make a distinction between CSAPA based on their history. All CSAPA have been included in TDI data since 2013, even though some centres only oversee a minority of DU, and sometimes none. This change explains the sudden increase in the number of CSAPA registered since.

The CSAPA are predominantly managed by not-for-profit non-governmental organisations. A minority of centres (approximately a third) are dependent upon a public health establishment. All are funded by the National Health Insurance Fund budget.

CSAPA in a prison setting, few in number (16), focus their activities on incarcerated drug users. Therapists at the CSAPA offer counselling for inmates that request it in the context of addiction medicine appointments. These are not drug-free zones like in certain countries. However, their activity only represents part of addiction health care delivery in a prison setting. On the one hand, addiction health care is delivered by general hospital or mental health establishments which provide health care in a prison setting. However, no information system exists able to measure this activity. On the other hand, the public authorities wished to set in place, as from 2011, a reference CSAPA for each of the 182 prisons in France (See Prison workbook). These CSAPA are responsible for intervening in custody to ensure

continuity of care. A financial budget has been planned to allow each reference CSAPA to dedicate an additional part-time social worker to intervention alongside incarcerated drug users or those having recently left prison.

In France, the activity of the CAARUD (low-threshold structures) is not perceived as falling within the scope of treatment: the information relating to this type of facility are detailed in the "Harms and harm reduction" workbook.

### *The general scheme*

The activity of office-based general practitioners with regard to treatment of drug use is described via the *Santé Publique France* Health Barometer general practitioner survey, conducted on a sample of practitioners. However, this survey has not been conducted since 2009. In 2009, two thirds of general practitioners (about 40,000) saw at least one opioid-addicted drug user in the last year (Gautier 2011). The proportion of those receiving at least one user per month substantially increased to almost 50% (compared to one-third in 2003) and 12% (about 7,000) received at least 5 user per month. This substantial level of activity alongside opioid-dependent drug users is mainly related to the prescription of opioid substitution treatment (OST). Appointments related to cannabis concern considerably fewer physicians: nearly 3,000 claim to have seen at least 5 patients per month related to cannabis use. Lastly, approximately one in five physicians (13,000) saw at least one patient in the course of the year for problem stimulant use. In 2016, independent prescribers of opioid substitution medications predominantly correspond to general practitioners (96.2%) and, more rarely, psychiatrists (3.5%) (Brisacier 2018).

In 2017, 51 medical micro-structures were established in seven regions and followed up nearly 1,700 clients: mainly in Grand-Est (where they were first created in Strasbourg back in 1999), Hauts-de-France, PACA, Bourgogne-Franche-Comté, and more recently Occitanie, Ile-de-France and Auvergne-Rhône-Alpes. A micro-structure is a multidisciplinary healthcare team working within a general practitioner's clinic, consisting of the GP, and at least a psychologist and social worker. It represents a primary care unit and is part of the nationwide first-line care network. Its target population consists of patients in complex situations in terms of addictive behaviours, unstable situations or with comorbidities related to drug use. A national micro-structure network coordination scheme was created in 2006 (Coordination nationale des réseaux des microstructures 2018).

Illegal drug users may also be treated in an outpatient setting at numerous addiction medicine clinics created in general hospitals and psychiatric clinics. In 2010, approximately 480 hospital addiction medicine clinics were registered (Palle *et al.* 2012). This figure refers both to clinics open for a few hours a week and those which operate every working day. Patients are mainly seen for alcohol problems; however all clinics may treat illegal drug users.

### **Outpatient drug treatment system – Client utilisation**

According to the data provided in the CSAPA activity reports, the approximate number of individuals admitted in outpatient CSAPA is 138,000<sup>1</sup> in 2016 for problem use of illegal drugs or misappropriated psychoactive medicines. This figure includes clients already receiving treatment the previous year. It is much higher than the number of people registered as starting a new course of treatment according to the definition in the TDI protocol (58,077 in 2017). This discrepancy is related both to the difference in the definition, and also to the exhaustiveness of the data originating from progress reports, whereas numerous CSAPAs do not take part in TDI data collection or, even if they do take part, do not provide data which can be used to determine whether a patient is starting or continuing treatment.

The number of DU seen by general practitioners is estimated at 132,000 based on the reimbursements for prescription of OST.

In 2016, the 11 CSAPA in a prison setting having contributed data on the number of patients claimed to have treated approximately 4,500 individuals in the past year for use of illegal drugs or psychoactive medicines. Extrapolating these figures, the total number of patients treated in these CSAPA can be estimated at approximately 6,000. However, the treatment of incarcerated drug users is also provided by outpatient CSAPA, carrying out activities not limited to prison-based interventions. In 2016, 202 CSAPAs claimed to operate in the prison setting. Overall, the number of prison inmates treated for psychoactive medicine or illicit drug use can be estimated at approximately 15,000. These figures are, however, partly included in the 138,000 drug-treatment clients in outpatient CSAPA.

<sup>1</sup> These figures take into account a 5% proportion of double entries of declared data, a percentage evaluated based on the last capture-recapture study conducted in a few French towns.

*T1.2.2 Optional. Please provide any additional information you feel is important to understand the availability and provision of Outpatient treatment within your country.*

**Table I.** Network of outpatient treatment facilities (total number of units and clients)

	<b>Total number of units</b>	<b>National Definition (Characteristics/Types of centre)</b>	<b>Total number of clients</b>
<b>Specialised drug treatment centres (CSAPA)</b>	377	Drug users having been seen at least once in the year as part of a meeting in person with a healthcare professional employed at a CSAPA in the context of structured treatment. Facilities of a medical-social nature authorised and funded by the Social Security scheme, the activity of which completely focuses on the treatment of individuals addicted to illegal drugs, alcohol and tobacco or with a behavioural addiction (gambling, cyberaddiction). These facilities are known as national treatment and prevention centres for addiction (CSAPA).	138,000
<b>Low-threshold agencies</b>	160	Drug users seen at least once at a CAARUD or seen externally by a team from the CAARUD. In France, drug users seen at a CAARUD are not considered as receiving treatment.	60,000
<b>General primary health care (e.g. GPs)</b>	30,000	Individuals having benefited from reimbursement further to prescription of opioid substitution treatment. Estimated number of general practitioners having claimed to have seen at least one opioid client in the past month.	132,000
<b>General mental health care</b>			
<b>Prisons</b>	16	Facilities authorised and funded by the Social Security scheme, the activity of which completely focuses on the treatment of incarcerated individuals addicted to illegal drugs, alcohol and tobacco or with a behavioural addiction (gambling, cyberaddiction). These facilities are known as national treatment and prevention centres for addiction (CSAPA) in a prison setting.	6,000
<b>Other outpatient units</b>			

**Source:** Standard table 24.

Note: These data are an estimation of all individuals treated over the past year in CSAPAs, whether for a new course of treatment or not. These figures are comparable to those obtained for other types of facilities. If these data are limited to TDI figures (58,077 individuals in 2017), it would not then be possible to provide figures for other types of facilities.

**T1.2.3 Optional.** Please provide any additional information on treatment providers and clients not covered above. (Suggested title: Further aspects of outpatient drug treatment provision and utilisation.)

## Inpatient network

T1.2.4 Using the structure and data provided in table II please provide an overview and a commentary of the main bodies/organisations providing Inpatient treatment within your country and on their respective total number of clients receiving drug treatment.

### **Inpatient drug treatment system – Main providers**

As for an outpatient setting, residential treatment may have a role in the context of a CSAPA or public, general or specialised psychiatric hospital.

#### *Residential care in CSAPAs*

CSAPA with housing offer different types of services. The most important in terms of the number of patients concerned, corresponds to collective housing in the context of residential treatment centres (CTR). These centres were historically created to receive drug users after withdrawal for stays over a few months, allowing them to readjust to life without drugs. Since OST became more widespread in the 1990s, these institutions are also open to individuals receiving this type of treatment. There are 35 CTR in 2016. In addition to these institutions, 9 therapeutic communities (TC), created in the 2000s, also exist. TC are now part of CSAPAs. All CTR and TC are administered by non-governmental bodies. It can also be observed that TC have a considerably higher number of spaces compared to CTR (30 vs. 10 on average). CSAPA with housing, as well as those in an outpatient setting, may offer housing services in residential therapeutic apartments (ATR), for stays of not more than two years. In 2016, 61 CSAPA offered stays in ATR. Lastly, there is also another type of service: short stays which meet the requirements of emergency housing for homeless drug users or transitional housing (notably for newly released inmates). In 2016, there were 7 CSAPA offering this kind of service.

#### *Residential care in hospitals*

Further to the 2007-2011 Plan for addiction treatment and prevention (Ministère de la santé et des solidarités 2006), les the resources available for residential treatment of addiction were considerably increased. In 2010, there were 391 hospitals in France, practically all public, equipped with hospital beds for withdrawal and 113 offering aftercare activities including addiction medicine (Palle *et al.* 2012). These services cover all types of addiction (notably alcohol), hence it is difficult to identify those which are actually open to drug users.

### **Inpatient drug treatment system – Client utilisation**

Based on the CSAPA activity reports, the number of individuals housed by CTR (residential treatment centres) and TC (therapeutic communities) may be estimated at 1,800 in 2016. Around 1,000 individuals were housed in ATR (residential therapeutic apartments) and about 600 were housed in an emergency or transitional facility run by a CSAPA. The parallels with drug users seen in outpatient CSAPA are undoubtedly fairly broad: a large proportion of the individuals received are, in fact, referred by an outpatient CSAPA.



*T1.2.5 Optional. Please provide any additional information you feel is important to understand the availability and provision of Inpatient treatment within your country.*

--

**Table II.** Network of inpatient treatment facilities (total number of units and clients)

	<b>Total number of units</b>	<b>National Definition (Characteristics/Types of centre)</b>	<b>Total number of clients</b>
Hospital-based residential drug treatment	na		na
Residential drug treatment (non-hospital based)	35	<p>Individuals housed in residential treatment centres</p> <p>Residential treatment centres are facilities which combined collective housing and treatment. It carries out the same missions and services as in an outpatient setting. It offers support for customised treatment.</p> <p>It is aimed at individuals, including those on OST, who need a structured framework together with temporary distancing, a break from their usual environment. It offers a variety of approaches: medical and psychological treatment, support, socialisation (activities and community life, but with a different approach to the therapeutic community), and socioprofessional reintegration.</p>	1,500
Therapeutic communities	9	<p>Individuals housed in experimental therapeutic communities.</p> <p>Therapeutic communities are housing facilities which target users dependent on one or more psychoactive substances, aiming for a goal of abstinence, with the specific feature of placing the group at the heart of the therapeutic and social integration project.</p>	300
Prisons	na		na
Other inpatient units	61	<p>Individuals housed in residential therapeutic apartments</p> <p>Housing in therapeutic apartments allows individuals followed up in the context of medical, psychosocial and educational care (outpatient follow-up) to regain their autonomy and re-establish their social relationships (e.g., by sharing daily tasks in the apartment) and professional relationships (searching for training, employment, etc.). This type of housing aims to prolong and reinforce the therapeutic action undertaken. It particularly aims at individuals receiving major treatment (OST, HCV, HIV).</p>	900
Other inpatient units	7	<p>Individuals housed in emergency or transitional facilities</p> <p>Short stays, in emergency or transitional facilities, are intended for counselling over short periods (less than three months), during which the user's health and social situation is assessed and medical, psychosocial and educational care proposed.</p> <p>This should enable a break and/or transition period (initiation of OST, awaiting withdrawal, newly released inmates, etc.) which is conducive to initiating a treatment process.</p>	600

Short-stay housing may be collective (such as in a residence) or individual (hotel stays).
--

na: not available

**Source:** Standard table 24

*T1.2.6 Optional. Please provide any additional information on types of treatment providers and its utilisation not covered above.*

(Suggested title: Further aspects of inpatient drug treatment provision and utilisation.)

## T1.3 Key data

The purpose of this section is to provide a commentary on the key estimates related to the topic. Please focus your commentary on interpretation and possible reasons for the reported data (e.g. contextual, systemic, historical or other factors but also data coverage and biases). Please note that for some questions we expect that only some key TDI data to be reported here as other TDI data are reported and commented in other workbooks (drugs, prison, harm and harm reduction, etc.). However, please make cross-references to these workbooks when it supports the understanding of the data reported here.

T1.3.1 Please comment and provide any available contextual information necessary to interpret the pie chart (figure I) of primary drug of entrants into treatment and main national drug-related treatment figures (table v). In particular, is the distribution of primary drug representative of all treatment entrants? (Suggested title: Summary table of key treatment related data and proportion of treatment demands by primary drug)

### **Summary table of key treatment related data and proportion of treatment demands by primary drug**

In 2017, almost 58,100 drug-treatment clients in a CSAPA setting were included in TDI data, compared to approximately 56,500 in 2016.

Nearly 69% of outpatient CSAPAs took part in the RECAP survey from which the TDI data are extracted. However, data may be missing for numerous patients for each CSAPA (missing data on substances or type of treatment). The rate of coverage<sup>1</sup> probably therefore ranges from 60% to 65% and, without this information, these patients are excluded from the TDI data. Centres which did not provide data do not seem to display common characteristics which would distinguish them from those having submitted data. Drug users at centres contributing to the TDI may therefore be considered as representative of all patients seen at CSAPA in an outpatient setting.

For the first time since 2009, the proportion of new patients treated for cannabis problems in CSAPAs decreased between 2016 and 2017 (- 3 points) to fall below 60% (Figure I). Opioid users represent the second largest group in France. Their share has fallen sharply over the last four years (from nearly 35% in 2013 to 26% in 2016) and has increased slightly in 2017. However, individuals for whom stimulants are described as the primary drug only represent a small proportion of new patients. Cocaine is described to a much lesser extent than cannabis or opiates as the primary drug (approximately 8% of new patients); however, it has been growing in proportion since 2015 (+ 32%), consistent with the increase in last-year use in France observed between 2014 and 2017 (see Stimulants section in the "drugs" workbook).

The total number of individuals on treatment is only known for CSAPA. It is not currently possible to determine the number of individuals admitted in hospitals, or the proportion of patients seen by a primary care practitioner having also been treated at a CSAPA in the last year.

It is likely that the distribution according to the primary drugs could be less imbalanced in favour of cannabis if clients in treatment for a drug use problem in non-CSAPA hospitals and in a primary care setting were also taken into account. Youth Addiction Outpatient Clinics, which predominantly offer counselling for cannabis users are usually linked to a CSAPA and much more rarely to a hospital, and the management of cannabis users is therefore less common in these healthcare institutions than in specialist centres. Primary care practitioners above all treat opioid users. However, only around 10% of the latter are prescribed opioid substitution treatment for the first time by a primary care practitioner (Brisacier 2018) and, in some cases, following on from prescription in a CSAPA, in which case, the latter would not be taken into account. The respective proportions of cannabis and opioids in terms of treatment would undoubtedly be modified, although more than likely to a limited extent.

The extent of treatment related to cannabis in France is partly explained by the declining proportion (which nonetheless remains fairly high) of clients referred to a CSAPA by the judicial authorities further to arrest for use of this substance (approximately 36% in 2016, based on TDI figures), but also by the measures taken by the public authorities faced with levels of substance use causing France to rank as the country with the highest substance use among 16 year-olds (The ESPAD Group 2016) and, more generally, as one of the countries with the highest substance use for the overall population. In response to incentives from public authorities (creation of youth addiction outpatient clinics, see T.1.4.1 below), CSAPA have therefore put considerable effort into providing counselling for this population, as shown by a substantial increase in the number of cannabis users treated in a CSAPA setting, particularly since 2010 (+ 21,000 clients initiating treatment or already followed up between 2010 and 2016) (Palle and Rattanatray 2018). As this usually involves short-term treatment, in contrast to opioid users, the number of clients able to receive counselling is limited more slowly by the available counselling facilities. Conversely, the number of opioid users treated in a CSAPA setting tends to decrease, which may partly stem from the fact that, due to readily accessible OST in France, referral via a CSAPA is required to a lesser extent.

<sup>1</sup> This coverage rate is calculated using the estimated number of people entering treatment within the year in all CSAPA as the denominator.

*T1.3.2 Optional. If possible, please provide any available information on the distribution of primary drug in the total population in treatment.*  
(Suggested title: distribution of primary drug in the total population in treatment.)

*T1.3.3 Optional. Please comment on the availability, validity and completeness of the estimates in Table V below.* (Suggested title: Further methodological comments on the Key Treatment-related data.)

### **Further methodological comments on the key treatment-related data**

The total number of clients in treatment is not known. Firstly, no statistical sources are available on drug users receiving counselling in an outpatient setting as part of non-CSAPA hospital addiction medicine appointments. As regards general practitioners, the number of patients in treatment may be estimated based on the number of patients reimbursed for OST. However, an unquantified proportion of these patients may have already been included among clients treated in a CSAPA setting. The total number of clients in treatment more than likely lies between 200,000 and 300,000 individuals.

**T1.3.4 Optional.** Describe the characteristics of clients in treatment, such as patterns of use, problems, demographics, and social profile and comment on any important changes in these characteristics. If possible, describe these characteristics of all clients in treatment. If not, comment on available information such as treatment entrants (TDI ST34).  
(Suggested title: Characteristics of clients in treatment.)

**T1.3.5 Optional.** Please provide any additional top level statistics relevant to the understanding of treatment in your country. (Suggested title: Further top level treatment-related statistics.)

**Tableau V.** Summary table - Clients in treatment


	Number of clients
<b>Total number of clients in treatment</b>	na
<b>Total number of OST clients</b>	170,000
<b>Estimated total number of all clients entering treatment in a CSAPA</b>	89,300*

na: not available

\* based on a coverage rate of 65%

**Source:** Standard Table 24 and TDI

**Figure I.** Distribution of the number of individuals having started treatment in a CSAPA in 2017, according to the primary drug (%)



**Source:** TDI

## T1.4 Treatment modalities

The purpose of this section is to:

- Comment on the treatment services that are provided within Outpatient and Inpatient settings in your country, with reference to the categories and data reported in SQ27 part 1 where possible. provide an overview of Opioid Substitution Treatment (OST) in your country

### Outpatient and Inpatient services

T1.4.1 Please comment on the types of outpatient drug treatment services available in your country and the scale of provision, as reported to the EMCDDA in SQ27 part 1.

#### Outpatient drug treatment services

In terms of outpatient treatment provision, other than measures relating to OST (widely available), the public authorities have primarily attempted to develop counselling and treatment specific to young users (for whom addiction problems are even more often intertwined with adolescent problems and their associated psychological difficulties), by particularly targeting adolescents and young adults who use cannabis. Created in 2004 [[Cirulaire DGS/DHOS/DGAS n°2004-464 du 23 septembre 2004 relative à la mise en place de consultations destinées aux jeunes consommateurs de cannabis et autres substances psychoactives et leur famille](#)], 90% of youth addiction outpatient clinics (CJC) are managed by a CSAPA (association or hospital-based management) and the remainder by hospitals and other types of facilities (youth reception and counselling centres (PAEJ), health counselling facilities for adolescents and their parents ). Approximately 540 clinics are currently in operation (Obradovic 2015; Protais *et al.* 2016) Their opening hours can vary (sometimes half a day each week, sometimes every working day). Numerous CJC have opened advanced clinics in schools or different youth facilities (such as PAEJ, youth reception and counselling centres, which are counselling structures on health issues for adolescents and their parents). This resource is available throughout France, and may be perceived to have a high level of accessibility. A best practices guide intended for professionals operating in the context of CJC, issued by the professional body for those working in the field of addiction medicine (Fédération addiction 2012) was published in 2012.

As regards other target groups mentioned in the EMCDDA SQ27P1 questionnaire (*Treatment availability*), no national "programmes" comparable to the resources set in place for young users currently exist. However, some CSAPA are committed and specialise in the specific treatment of different populations, such as individuals presenting psychiatric comorbidities, for whom specific protocols have been set in place. Nonetheless, no specific information is available on this subject. The issue relating to the treatment of pregnant women or new mothers has also long been a concern of the public authorities as well as healthcare professionals working in the field of addiction medicine. The 2008-2011 Government action plan against drugs and drug addiction (MILDT 2008) aimed to encourage projects along these lines. Further to a call for tenders, approximately forty projects have been funded, all contributed by CSAPA (Mutatayi 2014). Two residential treatment centres, located in two different regions (Aquitaine and Île-de-France), are entirely or highly specialised in the treatment of this type of population.

In a hospital setting, addiction liaison and treatment teams (ELSA) also regularly work with maternity units, either directly with patients or to train the personnel.

In the context of early referral into treatment ordered by the public prosecutor's office or courts (see "Legal framework" workbook) further to a drug-related offence, health care

delivery is available for this type of population. However, it is undoubtedly not always adapted to the needs of the population concerned, particularly newly released inmates, for whom housing is an acute problem. To prevent breaks in care and “cold releases”<sup>1</sup>, as part of the 2008-2011 governmental plan on drugs, the public authorities implemented experimental, rapid access, short-stay admission programmes in social and medical-social structures (with housing) for newly released inmates. In two years (2009-2010), seven programmes targeting newly released inmates were thus funded (4 projects of rapid access, short-stay units and 3 projects of early CSAPA consultations in social housing and rehabilitation centres) and then assessed by the OFDT (Obradovic 2014). The public authorities recently promoted the implementation of an experimental programme for the prevention of subsequent offences and an alternative to imprisonment among drug users having committed criminal acts related to their addiction, within the jurisdiction of a Paris court<sup>2</sup>. This experimental programme (the “Bobigny city project”) was initiated in March 2015. The objective is to invite approximately fifty multiple offenders to follow an intensive treatment programme (five hours of activities and treatment per day, five days a week, for a year) rather than returning to prison.

Numerous CSAPA also face the situation of counselling homeless drug users. Although some have specialised in counselling this population, their number is not sufficient. A programme called “*Un chez soi d’abord*” (inspired by the north-American *Housing first* program) has been trialled in four French towns (Paris, Lille, Marseille and Toulouse). It is not specifically aimed at drug users but homeless individuals suffering from major psychiatric disorders, a population which partly covers drug users without fixed abode. Recruited individuals are offered access to ordinary housing in return for intensive health and social support. This support is provided by teams bringing together both health professionals (psychiatrists, addiction specialists, general practitioners, nurses) and social workers, housing specialists or even individuals having experienced life on the streets or mental illness. This programme is accompanied by an evaluation study based on data collection from participants and qualitative interviews not yet performed in 2017. The evaluation study programme and protocol have been described in a publication (Tinland *et al.* 2013).

In the absence of a systematic survey on the development of specific counselling for the population listed in the SQ27P1 questionnaire, it was not possible to obtain information on counselling for seniors, sex workers or the LGBT community.

There is undoubtedly a need to develop specific programmes for these populations; however, the treatment of pregnant women or women with children, as well as individuals suffering from psychiatric problems or arrested for a drug-related offence, represents some of the situations which all CSAPA should be able to face. Training of CSAPA personnel and the development of specific “programmes” are most likely ways in which this goal can be achieved.

As a general rule, appointments with psychologists or psychiatrists are fairly widely available in CSAPA in an outpatient setting. The availability of the other types of services mentioned in the SQ27P1 is not known.

<sup>1</sup> Releases from prison without any therapeutic follow-up.

<sup>2</sup> The project run by the Bobigny courts is inspired by those existing in Canada (Montreal, Vancouver) which are based on an all-round approach to the individual and reinforced collaboration between the different protagonists of the programme, particularly in the health and judicial fields. Individuals with a complex psychiatric profile cannot be included in this programme.

*T1.4.2 Optional. Please provide any additional information on services available in Outpatient settings that are important within your country.*

(Suggested title: Further aspect of available outpatient treatment services)

T1.4.3 Please comment on the types of inpatient drug treatment services available in your country and the scale of provision, as reported to the EMCDDA in SQ27part 1.

(Suggested title: Inpatient drug treatment services)

### **Inpatient drug treatment services**

As a general rule, OST and appointments with psychologists or psychiatrists are fairly widely available in France in hospital addiction medicine departments, residential treatment centres, experimental therapeutic communities and residential therapeutic apartments. The availability of the other types of services mentioned in the SQ27P1 is not known.

*T1.4.4 Optional. Please provide any additional information on services available in Inpatient settings that are important within your country.*

(Suggested title: Further aspect of available inpatient treatment services)

*T1.4.5 Optional. Please provide any available information or data on treatment outcomes and recovery from problem drug use.* (Suggested title: treatment outcomes and recovery from problem drug use)

*T1.4.6 Optional. Please provide any available information on the availability of social reintegration services (employment/housing/education) for people in drug treatment and other relevant drug using populations.*

(Suggested title: Social reintegration services (employment/housing/education) for people in drug treatment and other relevant populations)

## **Opioid substitution treatment (OST)**

T1.4.7 Please provide an overview of the main providers/organisations providing OST within your country and comment on their relative importance.

(Suggested title: Main providers/organisations providing Opioid substitution treatment)

### **Main providers/organisations providing opioid substitution treatment**

There are two schemes available for dispensing treatments to people using illicit drugs: the specialised addiction treatment system (CSAPA) and the general healthcare system (hospitals and general practitioners).

OST is mainly prescribed in a primary care setting by general practitioners, and is usually dispensed in community pharmacies.

The organisation of access to OST is based on two different prescription frameworks, one for methadone, and the other for buprenorphine. Methadone, classed as a narcotic, has a more stringent prescription framework than buprenorphine (with or without naloxone). The

latter is a list I<sup>1</sup> drug, but is regulated by narcotics prescription and dispensing rules. This difference is related to the lesser danger involved with buprenorphine (a partial opioid receptor agonist) compared with methadone (a pure agonist), since buprenorphine's ceiling effect limits the depressant, and particularly cardiopulmonary depressant effects.

Methadone treatment must be initiated by physicians working in a CSAPA or a hospital (or in a prison health unit). Primary care physicians may provide follow-up care once patients have been stabilised. However, this restriction has been the subject of debate and the public authorities have questioned the advantages and disadvantages of allowing treatment with methadone to be initiated by primary care practitioners. The results of the Méthaville study published in November 2014 (Carrieri *et al.* 2014) support those in favour of extending initiation of methadone treatment to a primary care setting : similar results (whether initiation took place in primary care or at a CSAPA) regarding opioid abstinence and adherence to treatment, and better satisfaction among patients treated in a primary care setting. However, the study authors emphasise the fact that this result is determined by the willingness of primary care practitioners, through access to specific training on methadone prescribing and collaboration with a CSAPA and a reference pharmacist. Trialling of the initial methadone prescription in a primary care setting, envisaged in the previous 2013-2017 plan (MILDT 2013), is not mentioned in the 2018-2022 National Action Plan on Addiction (MILDECA 2018).

The methadone capsule form, which is more discreet than the large-volume syrup bottles and does not contain sugar or ethanol, is not intended for treatment initiation. It can be prescribed to patients taking the syrup form once they have been stabilised. Initial methadone capsule prescriptions can only be written by CSAPA or hospital physicians specialised in treating drug users. The maximum prescribing duration for this form is now 28 days as opposed to 14 in the past [[Arrêté du 13 octobre 2014 modifiant l'arrêté du 20 septembre 1999 modifié fixant la liste des médicaments classés comme stupéfiants dont la durée maximale de prescription est réduite à quatorze jours ou à sept jours](#)]. However, the syrup form maintains a maximum prescribing duration of 14 days.

Any physician can initiate buprenorphine treatment. The maximum duration of prescription is 14 days for syrup methadone, while it is 28 days for capsule methadone and buprenorphine. Both of these treatments are subject to controlled prescriptions.

Although the percentage of physicians prescribing OST has not significantly changed since 2003 (9 out of 10), the prescription structure has. More than one-third of these general practitioners prescribing an OST prescribed methadone in 2009, while the percentage prescribing buprenorphine is diminishing (from 84.5% in 2003 to 77% in 2009) (Gautier 2011).

<sup>1</sup> Medications dispensed only on medical prescription are included on list I (for those presenting high risks), list II (for those perceived as less hazardous) or on the narcotics list. Narcotics carry the risk of addiction with their use and are subject to controlled prescriptions.

T1.4.8 Please comment on the number of clients receiving OST within your country and the main medications used. (Suggested title: Number of clients in OST)

### **Number of clients in OST**

After first being marketed in 1995, buprenorphine very quickly became the leading treatment for opioid dependency in France. Since 2006, Subutex<sup>®</sup> is no longer the only product available. A number of generics have arrived on the market, seven in 2018, marketed by Arrow, Biogaran, Cristers, EG, Mylan, Sandoz and Teva. In January 2012, Suboxone<sup>®</sup> (a combination of buprenorphine and an opioid antagonist, naloxone) was launched in a



sublingual tablet administration form. The purpose of this combination is to prevent buprenorphine misuse, by provoking withdrawal symptoms when used by the injection route.

According to data from the national public health insurance centre (CNAM) collected from the EGBS database (simplified General sample of beneficiaries, sample of French persons with social security coverage), 162,300 individuals were reimbursed for opioid substitution medications dispensed in community pharmacies in 2017 (revised estimation taking into account the EGBS extrapolation coefficient and the representativeness of the EGBS evaluated at 95.6% of the population covered by the Social Security scheme). The number of people receiving opioid substitution treatment (OST), having risen constantly since it was first introduced in 1995, has remained stable since 2013. More than three-quarters of individuals reimbursed for opioid substitution medications are male. More specifically, in 2017, 99,900 individuals were dispensed buprenorphine in community pharmacies (Subutex® or generics), 61,700 methadone and 7,600 buprenorphine in combination with naloxone (Suboxone®).

Furthermore, 23,330 patients were dispensed opioid substitution medications in a CSAPA setting (19,800 methadone and 3,530 buprenorphine) in 2016, among the 56,200 patients followed up in a CSAPA setting and receiving OST (37,700 with methadone and 18,500 with buprenorphine) according to the data provided in the CSAPA activity reports (DGS/OFDT). In total, approximately 180,000 clients receive treatment with opioid substitution medications in France, taking into account possible duplicates between those treated by general practitioners, CSAPA, hospitals and in prison. The predominance of buprenorphine in opioid substitution medication sales, representing 64% overall, still clearly predominates, despite the growing proportion of methadone (Figure IV).

Morphine sulphate (generally sustained-release capsules) is used for substitution purposes in thousands of patients who mainly inject it. However, there is neither a legal prescription framework nor any benefit/risk assessment for the drug as substitution treatment.

#### *Initiation and maintenance of OST*

Approximately 16,600 individuals were dispensed OST in a primary care setting for the first time in 2016, i.e. 11% of patients reimbursed for OST over the year. Retention in treatment falls in the first two years, then stabilises. The proportion of clients still in treatment the year after first reimbursement is 62%, 47% two years later and 43% five years later. Retention in treatment is higher for clients receiving methadone than for those receiving buprenorphine in the first two years. This is then comparable (Brisacier 2018).

#### *Interrupting an opioid substitution treatment*

Among those patients dispensed OST in a primary care setting, nearly 13,700 patients stopped their OST in 2013 (without resuming treatment in the next three years), i.e. 9% of all clients reimbursed for OST over the year (Brisacier 2018). Many French addiction specialists and specialised psychiatrists are reluctant to fully withdraw substitution treatment too suddenly given the potential risk of relapse and overdose that may ensue. Unlike retention in treatment, discontinuing substitution treatment did not appear as a key objective in the 2004 consensus conference (FFA and ANAES 2005). However, many patients request discontinuation of their substitution treatment, leading health professionals to rethink their practices to determine strategies, indications and procedures that favourable to this kind of discontinuation (Dugarin *et al.* 2013; Hautefeuille 2013).

#### *Buprenorphine misuse and trafficking*

Some of the buprenorphine prescribed is misused and is not taken as part of a treatment programme. This proportion has diminished since the implementation of the French National Health Insurance Fund's 2004 strategy to control opioid substitution treatments<sup>1</sup>. One of the main indicators for buprenorphine misuse (average daily dose higher than 32 mg/d<sup>2</sup>) fell by

two-thirds between 2002 and 2007 (Canarelli and Coquelin 2009). Since then, this indicator has remained stable (3.1% in 2016) (Brisacier 2018). Moreover, 73% of patients receiving buprenorphine are receiving regular treatment<sup>3</sup> and therefore are integrated into a therapeutic process. People who are not regularly receiving these treatments are not necessarily cut off from any treatment strategy, just as users taking this medication as part of a treatment plan are not necessarily exempt from certain forms of misuse (INSERM 2012). Another indicator of misuse, the presence of multiple prescribers (5 and over) for the same beneficiary and several dispensing pharmacies (5 and over), included 3.7% and 3.5% of patients, respectively, taking buprenorphine in 2016 (Brisacier 2018). Factors associated with patients seeking multiple prescriptions (defined as prescriptions which overlap by one day or more and/or issued by at least 2 different prescribing physicians and/or dispensed in at least 3 different pharmacies) were male gender, low income, psychiatric disorders, concomitant use of hypnotic drugs, weak opioids and morphine (Delorme *et al.* 2016). Among CAARUD clients (2015 ENa-CAARUD survey), oral use (51%) was the most common route of administration for buprenorphine in 2015, ahead of injection (46%) which was the most widespread consumption pattern up to 2012. Oral use is on the increase, in contrast to injection which declined between 2012 and 2015. Snorting, less common (21%), after a marked increase between 2008 and 2012, showed a downward trend in 2015. Inhalation or smoking consumption patterns, although in the minority (7%), have been increasing since 2008 (Brisacier 2017). Improper buprenorphine use patterns, observed for several years, persisted in 2017, particularly among highly vulnerable users. This trend appears to be stable or even on the decline, particularly owing to "competition" arising from morphine sulphate in some regions (Milhet *et al.* 2017).

#### *Methadone misuse and risks*

National methadone dependence monitoring, placed under the responsibility of the CEIP-A (Centre for evaluation and information on pharmacodependence) in Marseille, was set in place when methadone capsules were placed on the market in 2008. The overview at 9 years reveals the increase in the number of patients treated with methadone, but also in the illegal procurement of methadone (5.9% in 2008 *versus* 9.7% in 2016) and in cases requiring hospital management. Furthermore, in year 9, there was an increase in methadone use among new or occasional users, and in the number of patients falling into a deep coma or attempting suicide. The mortality rate due to methadone is estimated at 2 deaths per 1,000 treated patients, this rate being 6 times higher than buprenorphine and 4.5 times higher than heroin. The Commission on narcotics and psychotropic substances wished to draw up an action plan with a view to bringing down the constant increase in the cases of overdose and deaths involving methadone (ANSM 2018).

#### *Substitution treatment in prison settings*

The proportion of inmates receiving OST was estimated in 2013 to be 7.8%, or approximately 14,900 people, of whom 61.6% were taking buprenorphine (Observatoire des structures de santé des personnes détenues (OSSD)) (see Prison workbook). The proportion was significantly higher in the female prison population in 2011 (16.5% among women *vs* 7.7% among men) according to the Prévacar study (Barbier *et al.* 2016).

<sup>1</sup> The French national insurance organisation (CNAMTS) controls introduced since 2004 primarily aim to identify dealers ("patients" as well as a few doctors and pharmacists) through reimbursement data. These controls red flag users who have at least five different prescribers or dispensing pharmacies, or who are being given a mean dose of more than 32 mg.

<sup>2</sup> The buprenorphine maintenance dose is 8 mg per day with a maximal daily dose of 16 mg. A mean daily dose of greater than 32 mg is a very suspicious indicator of buprenorphine trafficking or dealing.

<sup>3</sup> Patients taking regular buprenorphine treatment are subjects who let at least 35 days go by between prescription refills, or who sometimes wait longer (36-45 days) on at most three occasions. The maximum duration for which prescriptions are legally valid is 28 days.

**T1.4.9 Optional.** Describe the characteristics of clients in opioid substitution treatment, such as demographics (in particular age breakdowns), social profile and comment on any important changes in these characteristics. (Suggested title: Characteristics of clients in OST)

See Figure VIII for the age breakdown of opioid substitution medication beneficiaries.

**T1.4.10 Optional.** Please provide any additional information on the organisation, access, and availability of OST. (Suggested title: Further aspect on organisation, access and availability of OST)

## T1.5 Quality assurance of drug treatment services

The purpose of this section is to provide information on quality system and any national treatment standards and guidelines.

**T1.5.1 Optional.** Please provide an overview of the main treatment quality assurance standards, guidelines and targets within your country. (Suggested title: Quality assurance in drug treatment)

### Quality assurance in drug treatment

In 2017, in their concern for controlled treatment in compliance with current regulations for patients suffering from addictive behaviours and receiving OST, the national medical and pharmaceutical associations revised their joint professional guidelines for prescribing and dispensing opioid substitution medications, to facilitate access to care and improve patient management, compliance and follow-up (Conseil national de l'ordre des médecins and Conseil national de l'ordre des pharmaciens 2017). These guidelines point out that physicians and pharmacists have a duty to contribute to the management of addictive behaviours, notably by taking part in prevention, treatment and harm reduction measures related to the use of psychoactive substances, but also because they could always be held liable from a disciplinary, civil and criminal perspective.

In 2014, the medico-social system for the treatment of addictive behaviours was evaluated by the Interministerial Audit and Evaluation Office for Social and Health, Employment and Labour Policies (IGAS). In its conclusions, the IGAS confirmed the missions of the CAARUD and CSAPA and stated that *"the organisation and operation of these establishments meet the needs of the highly specific populations who turn to them"*. However, it recommends more stringent evaluation of *"the efficacy of the system, of its correct positioning and interaction with other protagonists in the prevention, health care, social and medico-social fields"* (Hesse and Duhamel 2014).

The latest national recommendations on therapeutic strategies for opioid-dependent individuals date back to the 2004 consensus conference (FFA and ANAES 2005).

In 2017, European experts published a consensus on best practices for methadone and buprenorphine use, by conducting an analysis of all guidelines published between 2014 and 2017 on this subject, supplemented by expert opinion based on clinical practice (Dematteis *et al.* 2017).

A guide on OST in a prison setting, published in 2013 (Ministère des affaires sociales et de la santé and MILDT 2013) describes in detail the legal and regulatory framework for OST (in France in general and in a prison setting) and gives recommendations for best practices in terms of treatment.

As regards youth addiction outpatient clinics, the publishing and distribution of the PAACT (Support and Alliance for Therapeutic Change) manual should be mentioned (Lascaux *et al.* 2014). This manual can be perceived as a best practice guide destined for CJC professionals and, more broadly, for all health professionals, who are the first point of contact and who aim to support young psychoactive substance users. Publication of this document on the initiative of professionals working in the CJC, but with the support of MILDECA and the Ministry of Health is clearly in line with the improvement in quality of care CJC.

## T2. Trends

The purpose of this section is to provide a commentary on the context and possible explanations of trends in treatment data.

T2.1 Please comment on the possible explanations of long term trends (10 years - or earliest data available) in the following treatment data:

- New treatment entrants (Illustrative figure II),
- All treatment entrants (Illustrative figure III),
- OST clients (Illustrative figure IV)

For example, patterns of drug use, referral practices, policy changes and methodological changes.

### Long term trends in numbers of clients entering treatment and in OST

#### *New treatment entrants*

Commenting on the changes in the absolute number of first-time treatment entrant is somewhat difficult owing to the particularly low coverage of this client category in terms of data collection. As stated above, a third of CSAPAs do not provide TDI data. Furthermore, the scope of the respondents varies considerably from year to year (some CSAPAs having never taken part in a survey decide to do so, whereas others decide to no longer take part). A large number of respondents do not state whether this is a client's first treatment in their lifetime or not. It is even more difficult to interpret the variations in terms of figures, due to the institutional changes which have led centres previously specialising in alcohol treatment to manage an increasing number of illicit drug users.

Keeping these reservations in mind, the figures seem to indicate a certain stability in the number of individuals admitted for treatment for the first time between 2007 and 2014. The sudden increase observed in 2015 is related to methodological changes and is not a reflection of a true variation in the treated population. Since 2015, the number of treated patients appears to be declining. Nevertheless, a large proportion of these changes could be related to variations in the scope of respondents.

As regards France, data on treatment demand seem particularly useful for observing changes in proportions. Since 2007, the proportion of cannabis users is increasing among individuals entering treatment for the first time in their lives (Figure II) whereas the proportion of opioid users is declining. However, since 2014, the respective proportions of cannabis and opiate users appear to have stabilised, fluctuating around 75% for cannabis and 14% for opiates. The proportion of cocaine, which remained fairly stable around 5 to 6% between 2008 and 2014, increased by nearly 2 points in 2017 reaching nearly 8%.

### *All treatment entrants*

As for users entering treatment for the first time, it is difficult to interpret these changes in absolute figures due to the problems arising from the variations in the scope of respondents. The substantial increase in the number of individuals included in TDI data between 2012 and 2013 is largely related to CSAPAs, previously specialising in alcohol treatment, being included in TDI data. As these CSAPAs mainly care for cannabis users (aside from alcohol users), the increases have almost exclusively arisen from this user category. The fact nonetheless remains that, in the long term, the number of cannabis users has increased considerably while the number of opiate users starting treatment has tended to decline. These users, for all substances combined, have increased in total since 2007, but to a lesser extent than imagined, taking into account the growing number of centres contributing to data collection.

As regards all treatment entrants (Figure IV), the distribution according to substances seems fairly stable up to 2010, with a slight downward trend in the percentage of cannabis users. Disregarding the values from 2012, probably partly incorrect, from 2011 a growing trend is observed among cannabis users, which continues, becoming more marked, up to 2016. These changes are symmetrical for the proportion of opiate users. The 2017 data seem to break with this trend. For the first time since 2010, the proportion of cannabis users is falling, and the proportion of opiate users is on the rise. Another striking phenomenon is the proportion of cocaine users which remained stable or, indeed, slightly declined between 2007 and 2015, and has since increased, particularly in 2017, in keeping with the growing use over the past year among the adult French population (see section on Stimulants in the Drug Use workbook).

The rise in the proportion of cannabis users may be explained both by the increase in cannabis use in France among teenagers and adults in the early 2010s, and by the mobilisation of the public authorities to increase the treatment provision for young cannabis users (see section on cannabis in the Drug Use workbook). It is always hazardous to interpret a variation which remains fairly low (- 2.7% in numbers in 2017) and which may be partly related to variations in the scope of respondents. The next few years will determine whether this concerns stabilisation in the proportion of users, as observed for clients starting treatment for the first time, or a more sustainable downward trend. The growing proportion of opiate users (+ 6.5% in numbers) may be compared with the restrictions in the sale of codeine medications introduced in July 2017 (see section T4.2) which may have led some individuals using these substances to seek help in a CSAPA.

### *OST clients*

Since 2010, the number of OST beneficiaries has been estimated based on National Health Insurance Fund reimbursement data (Figure VI). This had previously been estimated based on sales data for opioid substitution medications (OSM). In order to maintain the long-term developments, Figure VII shows the available data on OSM use since 1995.

Since 2013, the number of persons receiving OST has remained stable, after increasing constantly since this type of treatment was first introduced (Figure VI). The number of persons treated with buprenorphine has been decreasing slightly since 2014, in favour of patients treated with methadone whose numbers are increasing, in keeping with sales data for opioid substitution medications (Brisacier 2018).

The proportion of methadone continues to increase in compliance with the consensus conference recommendations on substitution treatments (FFA and ANAES 2005). The 2008 granting of the marketing authorisation for methadone capsules contributed to this increase. Since 2014, the syrup form no longer predominates. It is still exclusively prescribed to 31% of individuals having received reimbursement for methadone, compared to 57% for the

capsule form. Furthermore, 12% of beneficiaries were reimbursed for both forms (EGBS data, CNAM, processed by OFDT). According to sales data, in 2017, the syrup form represented 36% (versus 40% in 2016, 44% in 2015 and 55% in 2013) of the methadone sold (by weight) and the capsule form 64% (versus 60% in 2016, 56% in 2015 and 45% in 2013). Moreover, 80% of the quantities were dispensed in retail pharmacies, while 20% were in CSAPAs or hospitals (Bouchara data).

In 2017, the average age of patients dispensed opioid substitution medications in community pharmacies was 40.5 years (vs. 37.5 years in 2013). Men were older than the women on average (41.0 years vs. 39.2 years). Patients prescribed buprenorphine were older on average than those receiving methadone (41.8 years vs. 38.3 years). The most common five-year age groups are thirty-year-olds for clients receiving methadone (accounting for 45%), whereas those receiving buprenorphine are mainly in the age groups ranging from 35 to 49 (see figure VIII). The change in the age of patients receiving opioid substitution medications reflects the ageing of this population.


Figure VII presents the use of buprenorphine (including Suboxone<sup>®</sup>) and methadone in France since 1995. These data are based on sales and reimbursement figures, according to an assumed prescribed mean daily dose of 8 mg for buprenorphine (including Suboxone<sup>®</sup>) and 60 mg for methadone. Buprenorphine generics (introduced in France in 2006), and then Suboxone<sup>®</sup> (introduced in 2012) offset the decrease in Subutex<sup>®</sup> use observed since 2006.

In 2017, the quantities of buprenorphine sold (by weight) were as follows: Subutex<sup>®</sup> 74%, generics 21% and Suboxone<sup>®</sup> 5% (versus 1% in 2012) (Gers-Siamois, processed by OFDT).

The market penetration rate for buprenorphine generics (number of packs of generics reimbursed relative to the total number of packs of buprenorphine reimbursed) remained stable at 32% in 2017 (Assurance Maladie 2018).


*T2.2 Optional. Please comment on the possible explanations of long term trends and short term trends in any other treatment data that you consider important.  
In particular when there is a strong change in trend, please specify whether this change is validated by data and what are the reasons for those trends  
(Suggested title: Additional trends in drug treatment)*

**Figure II.** Trends in proportion numbers of first-time clients entering treatment, by primary drug, 2007-2017 (in %)




Source: TDI

**Figure III.** Changes in the proportion of patients starting treatment for the first time ever (substances unknown), 2007-2017 (in %)




Source: TDI

**Figure IV.** Trends in proportion numbers of all clients entering treatment, by primary drug, 2007-2017 (in %)



Source: TDI


**Figure V.** Changes in the proportion of patients starting treatment (substances unknown), 2005-2017 (in %)



Source: TDI



**Figure VI.** Trends in numbers of clients in opioid substitution treatment between 2010 and 2017




Note: The previous series ends in 2016, and took into account opioid substitution medications reimbursements for 86% of the population covered by the Social Security scheme. The new series starts in 2016, and includes reimbursement data for the whole population covered in France, estimated and readjusted based on EGBS data representing 96% of the covered population. These two series also include individuals with treatment dispensed in CSAPAs and in prison, which do not appear in National Health Insurance Fund reimbursement data.

OSM: opioid substitution medications

Source: Standard Table 24


**Figure VII.** Opioid substitution treatments: use of buprenorphine and methadone from 1995 to 2017 in terms of daily dose / 1,000 inhabitants aged 20 to 49 years / day (Subutex® and generics 8 mg/day, Suboxone® 8 mg/day, methadone® 60 mg/day)



HDB: high-dose buprenorphine

**Sources:** SIAMOIS (GERS, processed by InVS then OFDT), Bouchara-Recordati, Medic'AM (CNAM)

**Figure VIII.** Distribution of opioid substitution medication beneficiaries reimbursed in a community setting in 2017, by five-year age groups



OSM: opioid substitution medications

**Source:** EGBS (CNAM, processed by OFDT)

### T3. New developments

The purpose of this section is to provide information on any notable or topical developments observed in drug treatment in your country **since your last report**.

T1 is used to establish the baseline of the topic in your country. Please focus on any new developments here.

If information on recent notable developments have been included as part of the baseline information for your country, please make reference to that section here. It is not necessary to repeat the information.

Please structure your answers around the following question.

T3.1 Please report on any notable new or topical developments observed in drug treatment in your country since your last report. (Suggested title: New developments)

#### **New developments**

The proportion of new patients treated for a cannabis problem is high (59%), but decreased between 2016 and 2017. The proportion of opiate users followed a symmetrical progression to that of cannabis users. The proportion of cocaine users markedly increased between 2016 and 2017. The developments in 2017 contrast with the trends emerging in 2010-2011.

In 2017, 162,300 people received opioid substitution treatment dispensed in community pharmacies: 99,900 were prescribed buprenorphine (Subutex® or generics), 61,700 methadone and 7,600 buprenorphine in combination with naloxone (Suboxone®). Furthermore, 23,330 patients were dispensed opioid substitution medications in CSAPA (19,800 methadone and 3,530 buprenorphine) in 2016.

In March 2017, the Commission on narcotics and psychotropic substances approved the availability of a proprietary medicinal product containing buprenorphine for injection in the management of opioid-dependent patients. The target population consists of users who inject buprenorphine and/or other opioids and/or dependent on injection (ANSM 2017). The PrébupIV survey was conducted in France alongside a drug addict population injecting opioids, with a view to studying the factors associated with acceptability with respect to intravenous buprenorphine treatment. The vast majority (83%) claimed to be in favour of this type of treatment. Individuals mainly injecting buprenorphine, those reporting more complications related to injection and those never having overdosed were more favourable to receiving buprenorphine treatment for injection (Roux *et al.* 2017). The results of this study were, moreover, presented in a brochure destined for users, bringing together personal accounts and illustrations on buprenorphine treatment administered by injection (SESSTIM (UMR1252) and Aides 2018).

In December 2017, CNAM simultaneously launched national monitoring programmes for professionals and beneficiaries focusing on OST, and which are currently ongoing. Targeting and detection is based on reimbursements issued by the National Health Insurance Fund and examination of scanned prescriptions.

### T4. Additional information

The purpose of this section is to provide additional information important to drug treatment in your country that has not been provided elsewhere.

**T4.1 Optional.** Please describe any additional important sources of information, specific studies or data on drug treatment. Where possible, please provide references and/or links.  
(Suggested title: Additional Sources of Information.)

**T4.2 Optional.** Please describe any other important aspect of drug treatment that has not been covered in the specific questions above. This may be additional information or new areas of specific importance for your country.  
(Suggested title: Further Aspects of Drug Treatment.)

Medications containing codeine, ethylmorphine, dextromethorphan and noscapine were withdrawn from the list of medicinal products available over the counter, in the decree of 12 July 2017 [[Arrêté portant modification des exonérations à la réglementation des substances vénéneuses](#)] (see section T3.1 in the Legal Framework workbook), leading users in difficulty to visit general practitioners or CSAPAs, or to withdraw from the substance by themselves. The ANSM recommended withdrawal further to reports of several cases of substance abuse, including a fatal case at the beginning of 2017, among adolescents or young adults having taken purple drank (a mixture of a fizzy drink and cough medicine containing codeine, promethazine or dextromethorphan (ANSM 2018; Cadet-Tairou and Milhet 2017).

**T4.3 Optional.** Please provide any available information or data on psychiatric comorbidity, e.g. prevalence of dual diagnosis among the population in drug treatment, type of combinations of disorders and their prevalence, setting and population. If available, please describe the type of services available to patients with dual diagnosis, including the availability of assessment tools and specific services or programmes dedicated to patients with dual diagnosis. (Suggested title: Psychiatric comorbidity.)

## T5. Sources and methodology.

The purpose of this section is to collect sources and bibliography for the information provided above, including brief descriptions of studies and their methodology where appropriate.

**T5.1** Please list notable sources for the information provided above. (Suggested title: Sources)

### Sources

CSAPA activity reports (CSAPA are specialised drug treatment centres)

EGBS: General sample of French persons with social security coverage (*Échantillon généraliste des bénéficiaires simplifié*)

ENa-CAARUD survey: National survey of CAARUDs' clients (CAARUDs are low-threshold structures)

CJC survey: Survey in Youth Addiction Outpatient Clinics

RECAP: Common data collection on addictions and treatments

TREND: Emerging Trends and New Drugs

SIAMOIS: System of Information on the Accessibility of Injection Equipment and Substitution Products

- ANSM (2017). Compte rendu de la séance n°4 du 2 mars 2017. Commission des stupéfiants et psychotropes. Agence nationale de sécurité du médicament et des produits de santé, Saint-Denis.
- ANSM (2018). Retour sur la séance du 1er février 2018 de la Commission des stupéfiants et des psychotropes. Agence nationale de sécurité du médicament et des produits de santé, Saint-Denis. Available: [http://ansm.sante.fr/content/download/115539/1462135/version/1/file/Retour\\_CO\\_M\\_STUP\\_010218.pdf](http://ansm.sante.fr/content/download/115539/1462135/version/1/file/Retour_CO_M_STUP_010218.pdf) [accessed 19/06/2018].
- Assurance Maladie (2018). Medic'AM annuel 2017, tous régimes. Médicaments remboursés par l'ensemble des régimes de l'assurance maladie au cours de l'année 2017 [online]. Available: [https://www.ameli.fr/fileadmin/user\\_upload/documents/Medic\\_AM\\_annuel\\_2017\\_to\\_us\\_regimes.zip](https://www.ameli.fr/fileadmin/user_upload/documents/Medic_AM_annuel_2017_to_us_regimes.zip) [accessed 18/06/2018].
- Barbier, C., Maache, A., Bauer, D., Joannard, N. and Lerasle, S. (2016). Enquête flash relative à la prise en charge des addictions en milieu carcéral. Direction générale de la santé, Ministère des affaires sociales et de la santé.
- Brisacier, A.-C. (2017). Tableau de bord TSO 2017. OFDT, Saint-Denis. Available: <http://www.ofdt.fr/statistiques-et-infographie/tableau-de-bord-annuel-des-traitements-de-substitution-aux-opiaces/> [accessed 10/08/2017].
- Brisacier, A.-C. (2018). Tableau de bord « Traitements de substitution aux opiacés » 2018. OFDT, Saint-Denis. Available: <https://www.ofdt.fr/statistiques-et-infographie/tableau-de-bord-annuel-des-traitements-de-substitution-aux-opiaces/> [accessed 14/08/2018].
- Cadet-Taïrou, A. and Milhet, M. (2017). Les usages détournés de médicaments codéinés par les jeunes. Les observations récentes du dispositif TREND. Note 2017-03. OFDT, Saint-Denis. Available: <https://www.ofdt.fr/BDD/publications/docs/eisxax7.pdf> [accessed 20/07/2017].
- Canarelli, T. and Coquelin, A. (2009). Données récentes relatives aux traitements de substitution aux opiacés. Premiers résultats d'une analyse de données de remboursement concernant plus de 4 500 patients en 2006 et 2007 [Recent information on opioid substitution treatments. Initial results of a reimbursement data analysis on more than 4,500 patients in 2006 and 2007]. Tendances. OFDT (65).
- Carrieri, P.M., Michel, L., Lions, C., Cohen, J., Vray, M., Mora, M. *et al.* (2014). Methadone induction in primary care for opioid dependence: A pragmatic randomized trial (ANRS Methaville). PLoS One 9 (11) e112328.
- Conseil national de l'ordre des médecins and Conseil national de l'ordre des pharmaciens (2017). Recommandations ordinales. Prescription et dispensation des médicaments de substitution aux opiacés. CNOM, CNOP. Available: <http://www.ordre.pharmacien.fr/content/download/376626/1813620/version/1/file/Recommandations+ordinales++prescription+et+dispensation+des+m%C3%A9dicaments+de+substitution+aux+opiac%C3%A9s.pdf> [accessed 14/08/2018].
- Coordination nationale des réseaux des microstructures (2018). CNRMS. Rapport d'activité 2017.

- Delorme, J., Chenaf, C., Kabore, J.-L., Pereira, B., Mulliez, A., Tremey, A. *et al.* (2016). Incidence of high dosage buprenorphine and methadone shopping behavior in a retrospective cohort of opioid-maintained patients in France. Drug and Alcohol Dependence 162 99-106.
- Dematteis, M., Auriacombe, M., D'Agnone, O., Somaini, L., Szerman, N., Littlewood, R. *et al.* (2017). Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opinion on Pharmacotherapy 18 (18) 1987-1999.
- Dugarin, J., Dupuy, G. and Nominé, P. (2013). Arrêter la méthadone, pour quoi faire ? [Stop methadone, what for?]. Psychotropes 19 (2) 9-22.
- Fédération addiction (2012). Les pratiques professionnelles dans les Consultations Jeunes Consommateurs (CJC). De l'analyse des pratiques d'un réseau à l'élaboration de recommandations partagées. Fédération Addiction, Paris. Available: <http://www.federationaddiction.fr/cjc-le-guide-est-en-ligne/?aid=4209&sa=0> [accessed 10/08/2017].
- FFA and ANAES (2005). Conférence de consensus, Lyon, 23-24 juin 2004. Stratégies thérapeutiques pour les personnes dépendantes des opiacés : place des traitements de substitution. Textes des recommandations. ANAES (Agence nationale d'accréditation et d'évaluation en santé), Saint-Denis.
- Gautier, A. (2011). Baromètre santé médecins généralistes 2009. Inpes, Saint-Denis.
- Hautefeuille, M. (2013). Arrêter la substitution [Editorial]. Psychotropes 19 (2) 5-8.
- Hesse, C. and Duhamel, G. (2014). Evaluation du dispositif médicosocial de prise en charge des conduites addictives. IGAS (Inspection Générale des Affaires Sociales), Paris. Available: <http://www.ladocumentationfrancaise.fr/rapports-publics/144000578/index.shtml> [accessed 13/07/2017].
- INSERM (2012). Médicaments psychotropes : consommations et pharmacodépendances. INSERM, Paris.
- Lascaux, M., Couteron, J.P. and Phan, O. (2014). Manuel PAACT. Processus d'Accompagnement et d'Alliance pour le Changement Thérapeutique. Fédération Addiction, Paris.
- MILDECA (2018). Alcool, tabac, drogues, écrans : Plan national de mobilisation contre les addictions 2018-2022. Mission interministérielle de lutte contre les drogues et les conduites addictives, Paris.
- MILDT (2008). Plan gouvernemental de lutte contre les drogues et les toxicomanies 2008-2011. La Documentation française, Paris. Available: <http://www.drogues.gouv.fr/la-mildeca/le-plan-gouvernemental/les-precedents-plans> [accessed 10/08/2017].
- MILDT (2013). Government plan for combating drugs and addictive behaviours 2013-2017. MILDT, Paris. Available: [http://www.drogues.gouv.fr/sites/drogues.gouv.fr/files/atoms/files/plan\\_gouvernemental\\_drogues\\_2013-2017\\_eng\\_df\\_0.pdf](http://www.drogues.gouv.fr/sites/drogues.gouv.fr/files/atoms/files/plan_gouvernemental_drogues_2013-2017_eng_df_0.pdf) [accessed 12/06/2018].
- Milhet, M., Cadet-Taïrou, A., Lazès-Charmetant, A., Lose, S., Tissot, N., Zurbach, E. *et al.* (2017). Usages de BHD non conformes au cadre médical. De la buprénorphine au

"Subu" : observations récentes du dispositif TREND. OFDT, Saint-Denis. Available: <http://www.ofdt.fr/publications/collections/rapports/thema/usages-de-bhd-non-conformes-au-cadre-medical/> [accessed 20/07/2017].

Ministère de la santé et des solidarités (2006). La prise en charge et la prévention des addictions : plan 2007-2011. Ministère de la santé et des solidarités, Paris. Available: [http://solidarites-sante.gouv.fr/IMG/pdf/plan\\_addictions\\_2007\\_2011.pdf](http://solidarites-sante.gouv.fr/IMG/pdf/plan_addictions_2007_2011.pdf) [accessed 10/08/2017].

Ministère des affaires sociales et de la santé and MILDT (2013). Guide des traitements de substitution aux opiacés en milieu carcéral. Available: [http://solidarites-sante.gouv.fr/IMG/pdf/Guide\\_des\\_TSO\\_en\\_milieu\\_carceral.pdf](http://solidarites-sante.gouv.fr/IMG/pdf/Guide_des_TSO_en_milieu_carceral.pdf) [accessed 20/06/2018].

Mutatayi, C. (2014). Accueil addictologique et médicosocial de femmes toxicodépendantes. Expérience en 2010-2011. OFDT, Saint-Denis. Available: <http://www.ofdt.fr/BDD/publications/docs/eisxcmu3.pdf> [accessed 10/08/2017].

Obradovic, I. (2014). « Mesures d'accueil des sortants de prison ». Synthèse du focus group. OFDT, Saint-Denis. Available: <http://www.ofdt.fr/BDD/publications/docs/eisxiou4.pdf> [accessed 10/08/2017].

Obradovic, I. (2015). Dix ans d'activité des "consultations jeunes consommateurs". Tendances. OFDT (101).

Observatoire des structures de santé des personnes détenues (OSSD) (2014). Rapport d'exploitation des données 2013. DGOS, Ministère des affaires sociales, de la santé et des droits des femmes, Paris.

Palle, C., Canarelli, T., Bonnet, N., Borgne, A., Boyer, C., Breurec, J.Y. *et al.* (2012). Profil des patients en difficulté avec l'alcool accueillis à l'hôpital. Résultats de l'enquête 2010 sur les personnes reçues à l'hôpital pour addiction (ESPERHA). Tendances. OFDT (82).

Palle, C. and Rattanaray, M. (2018). Les centres de soins, d'accompagnement et de prévention en addictologie en 2016. Situation en 2016 et évolutions sur la période 2005-2016. Analyse des données des rapports d'activité des CSAPA. OFDT, Saint-Denis. Available: <https://www.ofdt.fr/publications/collections/rapports/rapports-d-etudes/rapports-detudes-ofdt-parus-en-2018/les-centres-de-soins-daccompagnement-et-de-prevention-en-addictologie-en-2016/> [accessed 17/10/2018].

Protais, C., Díaz Gómez, C., Spilka, S. and Obradovic, I. (2016). Évolution du public des CJC (2014-2015) [The evolution of population attending youth addiction outpatient clinic (CJC's) 2014-2015]. Tendances. OFDT (107).

Roux, P., Rojas Castro, D., Ndiaye, K., Briand Madrid, L., Laporte, V., Mora, M. *et al.* (2017). Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. Substance Abuse Treatment, Prevention, and Policy 12 (46).

SESSTIM (UMR1252) and Aides (2018). Enquête préliminaire à l'évaluation de la buprénorphine intraveineuse : étude PrébupIV.

The ESPAD Group (2016). ESPAD Report 2015. Results from the European School Survey Project on Alcohol and other Drugs. EMCDDA ; ESPAD, Lisbon.

Tinland, A., Fortanier, C., Girard, V., Laval, C., Videau, B., Rhenter, P. *et al.* (2013). Evaluation of the Housing First program in patients with severe mental disorders in France: study protocol for a randomized controlled trial. Trials 14 309.

T5.2 Where studies or surveys have been used please list them and where appropriate describe the methodology? (Suggested title: Methodology)

## **Methodology**

### **CSAPA activity reports: use of activity reports from the specialised drug treatment centres (CSAPA)**

*National Health Directorate (DGS) / French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

Since 1998, CSSTs (Specialised care centres for drug users), and then the CSAPAs that followed them, have been annually completing a standardised activity report and submitting it to their Regional Health Agency (ARS). These reports are then sent to the DGS, which processes them with the assistance of the OFDT. The aim of this data collection exercise is to monitor the activity of the centres and the number and characteristics of the patients received. Epidemiological data are not recorded patient by patient, but rather for all people received in the centre. For 2016, the reports from the 377 outpatient CSAPAs and 11 prison-based CSAPAs were analysed. The respective response rates were 100% and 69%.

### **EGBS: Échantillon généraliste des bénéficiaires simplifié [General sample of French persons with social security coverage]**

*National public health insurance (CNAM), processed by the French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

The population being dispensed an opioid substitution medication in the primary care setting was studied using data from the simplified French National Health Insurance Fund's "EGBS" general population sample. The EGB is a permanent representative sample of the population protected by the general health insurance scheme (excluding students and civil servants), the agricultural worker health insurance scheme (MSA) and the health insurance scheme for self-employed people (RSI). It comprises 1/97<sup>th</sup> of the list of Social Security numbers, grouping more than 700,000 beneficiaries in 2017. The database resulting from this sample contains some sociodemographic data and all reimbursed health services and treatments (medical consultations, medications and laboratory work, etc.). There are also medical data on treatment under the French ALD (long-term illness) scheme as well as hospital data from the Programme of Medicalisation of Information Systems (PMSI) covering medicine, surgery and obstetrics. The CNAM has made the EGB available to several health agencies, including the ANSM and OFDT. The 2011 and 2012 data were extracted by the ANSM, and the 2013 to 2017 data by the OFDT.

### **ENa-CAARUD: National survey of low-threshold structures (CAARUD)**

*French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

Conducted every two or three years since 2006 in all CAARUDs (on mainland France and in French overseas departments), this survey determines the number of users seen in these structures, the characteristics of these users and their use patterns. Each user who enters into contact with the structure during the survey undergoes a face-to-face interview with



someone working at the structure. The questions asked are on use (frequency, administration route, equipment-sharing), screening (HIV, HBV and HCV) and social situation (social coverage, housing, level of education, support from friends and family, etc.). The 2015 survey was conducted from 14 to 27 September: 3,129 individuals completed the questionnaire and were included in the analysis. Out of the 167 CAARUDs registered in France, 143 took part in the survey (i.e. 86%). The data collection rate (proportion of users for whom the questionnaire was completed relative to all users encountered during the survey in the CAARUDs having taken part in the survey) was 64% in 2015.

### **CJC survey: Survey in Youth Addiction Outpatient Clinics**

*French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

2015 is the fourth year (after 2005, 2007 and 2014) of the survey on clients of youth addiction outpatient clinics (CJC), a scheme created in 2005 to offer counselling for young psychoactive substance users. The 2015 survey is based on the responses by professionals having seen the patients or their families between 20 April and 20 June 2015. It covers mainland France and French overseas departments. Out of 260 facilities managing a CJC activity in mainland France and the DOM recorded in 2015, 199 responded to the survey, i.e., a response rate of 77%.

A year after a first survey in 2014, this second one reveals the evolution of the population attending the clinics following a communication campaign. In total, 3,747 questionnaires were collected during the 9-week inclusion period in 2015 (vs. 5,421 during the 14-week survey period in 2014), ensuring a stable base of facilities participating in both surveys: 86% of facilities responding in 2015 took part in both surveys.

The questionnaire comprises four parts: circumstances and reasons for consulting, user sociodemographic characteristics, substances used and evaluation of cannabis dependence by the Cannabis Abuse Screening Test, and decision made at the end of the appointment.

### **RECAP: Common Data Collection on Addictions and Treatments**

*French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

This system was set up in 2005 and continually collects information about clients seen in National Treatment and Prevention Centres for Addiction (CSAPAs). In the month of April, each centre sends its results from the prior year to the OFDT, which analyses these results. The data collected relate to patients, their current treatment and treatments taken elsewhere, their uses (substances used and substance for which they came in the first place) and their health. The common core questions help harmonise the data collection on a national level and fulfil the requirements of the European Treatment Demand Indicator (TDI) protocol.

In 2017, approximately 208,000 patients seen in 260 outpatient CSAPAs, 15 residential treatment centres and 3 prison based CSAPAs for an addiction-related issue (alcohol, illicit drugs, psychoactive medicines, behavioural addiction) were included in the survey.

### **SIAMOIS: System of Information on the Accessibility of Injection Equipment and Substitution Products**

*Groupe pour la réalisation et l'élaboration d'études statistiques (GERS) / French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

The system of information on the accessibility of injection equipment and substitution products (SIAMOIS) was designed in 1996 to monitor trends in terms of access to sterile injection equipment available in pharmacies and opioid substitution medications on a departmental level. No data are available from 2012 to 2015, but only from 2016 onwards.

**TREND: Emerging Trends and New Drugs**

*French Monitoring Centre for Drugs and Drug Addiction (OFDT)*

The aim of the TREND scheme, which was established in 1999, is to provide information about illegal drug use and users, and on emerging phenomena. Emerging phenomena refer either to new phenomena or to existing phenomena that have not yet been detected by other observation systems.

The system is based on data analysed by eight local coordinating sites (Bordeaux, Lille, Lyon, Marseille, Metz, Paris, Rennes and Toulouse) that produce site reports, which are then extrapolated to a national level using the following tools:

- continuous qualitative data collection in urban settings and in the party scene by the local coordination network, which has a common data collection and information strategy;
- the SINTES scheme, an observation system geared towards detecting and analysing the toxicological composition of illegal substances;
- recurring quantitative surveys, particularly among CAARUD clients (ENa-CAARUD);
- partner information system results;
- thematic quantitative and qualitative investigations that aim to gather more information about a particular subject.